B
IDXX icon

Bailard’s Idexx Laboratories IDXX Stock Holding History

Bailard’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Sell
2,153
-889
-29% -$570K 0.03% 296
2025
Q4 		$2.06M Buy
3,042
+479
+19% +$326K 0.05% 226
2025
Q3 		$1.64M Buy
2,563
+615
+32% +$373K 0.04% 266
2025
Q2 		$1.04M Buy
+1,948
New +$932K 0.02% 318
2022
Q2 		– Sell
-502
Closed -$275K – 736
2022
Q1 		$275K Buy
502
+159
+46% +$83.6K 0.01% 561
2021
Q4 		$226K Buy
+343
New +$215K 0.01% 647
2021
Q2 		– Sell
-729
Closed -$357K – 726
2021
Q1 		$357K Buy
729
+140
+24% +$70.1K 0.01% 462
2020
Q4 		$294K Buy
+589
New +$264K 0.01% 446

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bailard's IDXX Position: Q1 2026 in Review

Bailard reduced its Idexx Laboratories (IDXX) stake by 29% in Q1 2026, selling an estimated $570K and leaving 2,153 shares worth $1.21M. The position accounts for 0.03% of the portfolio, ranked #296.

Bailard first reported a position in IDXX in Q4 2020 and has held it in 8 quarters since. The position peaked at $2.06M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Bailard held 2,153 shares of Idexx Laboratories worth $1.21M as of Q1 2026.
  • Bailard sold 889 Idexx Laboratories shares in Q1 2026, an estimated $570K.
  • Idexx Laboratories made up 0.03% of Bailard's portfolio in Q1 2026, its #296 holding.
  • Bailard first reported a position in Idexx Laboratories in Q4 2020 and has held it in 8 quarters since.
  • Bailard's Idexx Laboratories position peaked at $2.06M in Q4 2025.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.